AMAG Pharmaceuticals, Inc. -- Moody's: No change to AMAG outlook following approval of generic hydroxyprogesterone caproate

New York, September 16, 2015 -- Moody's commented that there is no change to the B2 Corporate Family Rating or positive outlook of AMAG Pharmaceuticals, Inc. (AMAG) following the FDA approval of a generic hydroxyprogesterone caproate. The development is credit negative because the generic drug has the same active ingredient --and therefore could theoretically compete -- with AMAG's key product, Makena. However, Moody's does not believe that, practically, the drug will exert any meaningful market share or pricing pressure on AMAG's product over the rating horizon. Please go to www.moodys.com for our full issuer comment.

Vollständigen Artikel bei Moodys lesen